Drug Trial Radar · NCT07337447
Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01)
Last checked: Nov 19, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
122
Planned (sponsor's estimate)
Start
Apr 2026
Primary completion
Apr 2029
Study completion Apr 2030
Sponsor
- Lead sponsor
- Hospices Civils de LyonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Federation Francophone de Cancerologie Digestive
- First posted
- Jan 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Background Neuroendocrine carcinomas (NECs) of gastro-entero-pancreatic (GEP) or unknown (UK) origin are rare and highly aggressive diseases. The recommended first-line (L1) treatment is platinum-etoposide combination therapy, which has a progression-free survival (PFS) of only 4-9 months and a median overall survival (OS) of approximately 12 months. All patients experience relapse, often rapidly after this first line of chemotherapy. The standard second-line (L2) chemotherapies recommended by ESMO, ENETS, and NCCN, FOLFIRI and FOLFOX, have modest efficacy with a PFS of 3 months and a median OS of 6 months. The BEVANEC study (PHRCK 2014, NCT02820857) reported no benefit of FOLFIRI + bevacizumab compared to FOLFIRI in a randomized phase II study that enrolled 150 patients in 26 centers over a period of 5 years in France. To date, the most promising efficacy data for this highly aggressive cancer come from clinical trials of immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 checkpoint. For example, in France, the non-comparative phase II NIPINEC trial (NCT03591731) randomized patients to receive nivolumab +/- ipilimumab in L2/3 and achieved its primary evaluation criterion (ORR-8 weeks\>10%). Other trials in Europe and worldwide have also reported efficacy data in the context of single-arm studies. Scientific Questions and Unmet Needs: 1. New therapeutic options/perspectives are necessary for patients with GEP/UK NECs given the limited overall survival. 2. Approximately 50% of patients experienced early progression under immunotherapy in the NIPINEC trial and other trials, which may be explained by the absence of chemotherapy combined with immunotherapy and/or the existence of resistance mechanisms. 3. In the GEP/UK NEC indication, the design of these immunotherapy trials has been non-comparative single-arm studies because the realization of randomized comparative trials is considered very difficult for these very rare cancers (incidence \<5/million). Rationale for the REWENEC-01 Trial The DURIGAST PRODIGE 59 study, conducted by the FFCD, demonstrated the feasibility and safety of the FOLFIRI + double immune checkpoint inhibitor (anti-PD-1 and anti-CTLA4) combination, as well as for the combination Folfox-Domvanalimab-Zimberelimab (anti-PD-1 and anti-TIGIT). In a translational study of the immune phenotype in patients with NECs treated with the anti-PD1 pembrolizumab, an increase in TIGIT expression was observed after pembrolizumab treatment and higher TIGIT expression on T cells in the blood of patients with high Ki67 expression in their tumors. These data suggest that TIGIT is a potential complementary therapeutic target to PD-1/PD-L1 checkpoint inhibition in GEP/UK NECs. Domvanalimab has been developed as an anti-TIGIT monoclonal antibody and zimberelimab as an anti-PD-1. Design and primary objective of the REWNEC-01 Trial The REWENEC-01 trial is a comparative phase II trial that will randomize GEP/UK NEC patients between an experimental arm FOLFIRI+Zimberelimab + Domvanalimab and a control arm FOLFIRI in L2. The FOLFIRI arm will be a "hybrid" synthetic control arm composed of patients from historical/external data from the FOLFIRI arm of BEVANEC and French retrospective studies RBNEC and CEPD, mixed with patients recruited prospectively during the trial and randomized to the control arm. The randomization ratio for patients included prospectively during the trial will be 4:1 (4 patients assigned to FOLFIRI+Zimberelimab + Domvanalimab for 1 patient assigned to FOLFIRI). The randomization algorithm will take into account "external" patients assigned progressively to the control arm to obtain a 1:1 ratio between the trial arms, with balanced distributions of stratification factors between the two arms. With 77 patients to be included, this strategy will provide statistical power equivalent to that of a trial including 122 patients, sufficient to demonstrate an advantage in overall survival rate at 12 months from 32% to 50%. The hypotheses related to efficacy criteria are formulated a priori, as recommended by the FDA guidance document on trials with synthetic/external control arms. The proof of concept has been reported at ESMO 2023. The primary judgment criterion will be the overall survival rate at 12 months because it is a strong and significant criterion for translating the clinical benefit of the Chemotherapy + Zimberelimab + Domvanalimab combination. The design with a hybrid synthetic control arm allows for the consideration of a randomized comparative study in a cancer as rare as neuroendocrine carcinoma.
Conditions
- Carcinoma, Neuroendocrine
Interventions
FOLFIRI + Zimberelimab + DomvanalimabDrug
FOLFIRI every 14 days + Zimberelimab IV every 28 days + Domvanalimab IV every 28 days
FOLFIRI (standard of care)Drug
FOLFIRI every 14 days IV every 28 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (%) between FOLFIRI and FOLFIRI+Zimberelimab+DomvanalimabTime frame: 6 months after the start of treatment 12 months after the start of treatment
Locations
21 sites in 1 country. Site status is shown where the registry gives one.
CHU Amiens Picardie
Amiens, France
CHU Avicenne APHP
Bobigny, France
CHU Caen Normandie
Caen, France
Hôpital Beaujon
Clichy, France
Hôpital Henri MONDOR
Créteil, France
CHU Dijon
Dijon, France
CHU de Grenoble
Grenoble, France
Centre Oscar Lambret
Lille, France
Service d'Oncologie Médicale - Hôpital Edouard Herriot - Hospices Civils de Lyon
Lyon, France
CHU Timone
Marseille, France
Institut Paoli Calmettes
Marseille, France
CHU Montpellier - Hôpital Saint Eloi
Montpellier, France
HEGP
Paris, France
Hôpital Saint Antoine APHP
Paris, France
Hôpital Saint Louis APHP
Paris, France
CHU de Bordeaux - Hôpital Haut-Leveque
Pessac, France
CHU de Poitiers
Poitiers, France
Hôpital Robert Debré, CHU de Reims
Reims, France
CHU Rouen
Rouen, France
Centre Paul Strauss
Strasbourg, France
Institut Gustave Roussy
Villejuif, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.